Related Experiment Videos
[Movalis in osteoarthritis (results of Russian research)]
Aim:
Response and tolerance study of a novel nonspecific antiinflammatory drug meloxikam (movalis) in patients with osteoarthrosis (OA).
Materials And Methods:
630 OA patients entered a multicenter trial in 29 hospitals. Movalis was given in a dose 7.5 mg or 15 mg (groups 1 and 2, respectively). In poor response the dose 7.5 mg was raised to 15 mg. The course of treatment took 2-4 weeks. The effect was assessed in scores by changes in the complaints.
Results:
Movalis has a significant antiinflammatory and analgetic effect, improved joint function, diminished severity of arthralgia and synovitis. Side effects were occasional.
Conclusion:
Movalis introduction in wide rheumatological practice will raise effectiveness of OA treatment and reduce the risk of side effects.